Quinnova Pharmaceuticals Inc.
This article was originally published in Start Up
Quinnova Pharmaceuticals Inc.'s Proderm Technology delivery system is a water-lipid-based formulation designed to apply active ingredients to the skin for the treatment of inflammatory skin diseases. Several Proderm products are already on the market. The start-up's TwinDerm technology - a two-step, single-unit topical system that allows delivery of two products in sequence from a single pouch - is designed to make treatment simpler and more convenient, therefore improving patient compliance.
You may also be interested in...
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
Syntropharma Ltd. aims to take known drugs that can be improved via transdermal delivery, or gain product life-extension through reformulation in the novel delivery mechanism. The company is focusing on two candidates: a transdermal selegiline patch for depression (aimed at the European market) and a patch formulation of naltrexone, an opioid receptor antagonist for battling dependence on alcohol and opiates.
Ocelus Ltd. hopes to extend transdermal delivery to macromolecules. Its early-stage technology combines a microchip reservoir with microneedles that could painlessly inject precise yet tiny amounts of a drug into the skin at hundreds of sites per square centimeter. This could make administration simpler, and by reducing the pain associated with injectable drugs, improve patient compliance.